Leave the blockbusters to big pharma: Ipsen's 'opportunistic' approach to M&A paying dividends

21 February 2018

With 2017 sales growth at 21.5% and shares in the company up 96% since the beginning of last year, everything is going right for Ipsen (Euronext: IPN) at the moment.

The French drugmaker also reported core operating margin as a percentage of net sales was at a healthy 26.4% in presenting its annual results last week, when buoyant predictions were also made for the year ahead.

Ipsen estimated that group sales will grow by at least 16%, and predicted that core operating margin will be more than 28% of net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK